

## Prostate Cancer Program

Medical Director, David Golombos, MD

Cancer Program Nurse, Shannen Harbourne, RN, MSN

## **PSA Pre-screening Information**

The National Comprehensive Cancer Network (NCCN) has issued new guidelines for <u>prostate cancer screenings</u>. The guidelines were developed from a systematic literature review to ensure that men most likely to benefit from early detection are screened, and to encourage shared decision-making between the patient and physician:

Men who are considering PSA screening should now speak with their physician about the benefits and harms of testing to determine the best course of action.

Screening is for healthy men without a personal history of prostate cancer. Men with known prostate cancer should follow up with their diagnosing physician or seek consultation from a urologist.

Prostate cancer screening is not recommended for men <45 years of age, or those > 75 years old or with less than 10-15 years life expectancy. Men who are at higher risk of prostate cancer (race, family history, etc.) may be eligible to screen earlier starting at age 40.

To reduce the harms of screening, a routine screening interval of two years or more may be preferred over annual screening in those men who have participated in shared decision-making and decided on screening.

Prostate cancer is the most common malignancy and the second most common cause of cancer death in American men. The Prostate Specific Antigen (PSA) blood test and the digital rectal examination (prostate exam or DRE) may help identify prostate cancer in an early stage. This concept; however, has not been scientifically proven and is currently the subject of great debate. All men should be aware of the risks and benefits of screening including, but not limited to the following:

<u>Possible Benefits:</u> Finding prostate cancers that may be at high risk of spreading, so that they can be treated before they spread. In some men this may lower the chance of death from prostate cancer.

<u>Possible Risks:</u> The potential risks of the PSA test are largely related to the choices made based on the test results, such as the decision to undergo further testing and treatment for prostate cancer. These risks include:

**False positive test results:** This occurs when a man has an abnormal PSA test but does not have prostate cancer. False positive test results can lead to "unnecessary" tests, like a biopsy of the prostate.

**Biopsy complication:** A biopsy is a procedure that carries its own risks, including pain, bleeding and infection.

**Psychological effects:** False-positive test results can cause anxiety or distress. If you are diagnosed with prostate cancer, but it appears to be a slow-growing tumor that doesn't result in illness, you may experience significant anxiety knowing it's there which can impact your treatment decisions.

The best evidence supports the use of serum PSA for the early detection of prostate cancer. The value of a DRE as a stand-alone test is limited, and the prediction ability of a DRE in men with a normal PSA is poor. There is some evidence to support that a combination of PSA and DRE is more effective for the early detection of prostate cancer than either test alone. A DRE should be performed in all men with an abnormal PSA to aid in decisions regarding biopsy.

As a result, you are given the option of having a DRE during your screening.

If you have an abnormal PSA, a DRE is strongly recommended and should be performed by your physician during office follow up, or will be performed during a consultation visit with a urologist for an abnormal PSA

#### **Important Influencing Factors:**

The change in the PSA level from one test to the other is suggestive of risk and aggressiveness.

PSA Levels increase with age. Enlarged prostates can have higher PSA levels.

#### Factors that can affect the PSA level:

Prostatitis
BPH -Benign Prostatic Hypertrophy
Prostate Cancer
PSA level can be influenced by
Ejaculation 48 hours prior to testing,
Certain Medications
Rigorous Exercise

#### **Prostate Cancer Treatment:**

All risks and benefits of treatment must be discussed, including active surveillance. (having no surgical or pharmacologic treatment, unless the disease becomes more aggressive.)

## Urinary frequency, weak stream, do I have BPH???

Benign Prostatic Hyperplasia (BPH) is a common condition in men over 50 years of age, but may also develop in younger men. In most men, the prostate begins to enlarge in the fourth or fifth decade of life and continues to enlarge with advancing age. The cause of this enlargement has not been identified, and it *does not increase or decrease your risk of prostate cancer*. BPH is usually not a serious threat to your health, but it can seriously affect the quality of your life.

BPH often causes urinary frequency during the day and/or night and may cause sudden urges to urinate or urine leakage. Some men may notice a weak urinary stream and can have difficulty starting urination or difficulty in postponing urination when the urge occurs. There may be a sensation that the bladder is not emptying completely. These urinary symptoms often interfere with a good night's sleep. As a result, you may find yourself modifying your activities to be close to a bathroom. The symptoms can vary in intensity from day to day and progress at different rates in different men. To complicate matters further, the intensity is not always in proportion to the degree of enlargement. In addition, the symptoms of BPH overlap with those of other urinary problems.

Treatment must be individualized based on the cause, pattern and intensity of your type of problem. Treatment of symptomatic BPH ranges from medication in mild cases to various types of surgery for more severe cases. The medications used to treat BPH are usually taken once daily and are safe when prescribed properly and well tolerated by most men. There are several surgical techniques available to treat BPH in those men who do not respond to medication. Some of these can be performed on an outpatient or short stay basis and have low rates of complication and short recovery periods. Please talk to your doctor or urologist about these options and get their advice. If you have questions or need more information about this subject, an appointment can be made to see one of the Stony Brook urologists if desired. Please call Stony Brook Urology at **631-444-6270** 

Prostate Cancer Program
Stony Brook Medicine
24 Research Way
Suite 500, Setauket, NY 11733

For Screening Information: 631-444-4400



# **Prostate Cancer Screening Consent**

1 Tostate C	ancer bereening consent
	Date
Print Name	Screening Location
and sign this form and complete the attached	gram. In order to be screened, please read the consent entirely questionnaire. The screening will consist of a prostate specific ital rectal exam (DRE). Please arrive no earlier than fifteen ou.
You may eat normally. Be sure to come well hydrat rigorous exercise, including bicycle riding, 48 hours venipuncture to minimize bruising and blood loss. experience minor discomfort and/or occasionally, a the first 24hrs, in 15 minute intervals and warm page	ous blood specimen of approximately 10 ml. (about 2 teaspoons) from you. ed as it enhances the veins for blood drawing. Please avoid ejaculation and a prior to testing; please be sure to apply pressure to the site right after the Remove the bandage from the site after bleeding has stopped. You may bruise or infection may result You may apply a cold pack or ice to site for eks thereafter. Please remove the tape/band aid from the site as soon as the ram will not be responsible for expenses related to any further testing or
gland. The DRE may occasionally cause some disc physician finds any abnormality, we recommend y	wed index finger into the rectum and gently pressing against the prostate omfort and a desire to urinate which will not last long. If your examining you contact your personal physician or urologist for further testing. This sees related to any further testing or treatment if you should require it.
men with above average risk age 40-44) be of detection and risk assessment on an individu	rk (NCCN) recommends that all men 45 years and older, (or ffered a baseline PSA test and Digital Rectal exam for early al basis. The NCCN strongly urges that all men who have taken ir physician regardless of the result, to discuss the benefits of
consult. Please note that although some tumors	ommend you contact your personal physician or a urologist for may be detected by this exam, no test is completely accurate in the normal exam or PSA result does not necessarily imply the presence
You will receive a mailed letter with your DF	RE and PSA results within a few weeks.
responsibilities associated with it. I understand using the DRE and PSA tests and does not consinformation regarding the benefits and risks of discuss this issue prior to the testing with a lice although some tumors may be detected by the prostate cancer. For diagnosis of a medical primedical evaluation. I understand that the result care provider, if any I indicated on this form maintained within current legal limits. They will access to these records will be strictly limited.	cancer screening program, I recognize and accept all risks and that this program will only screen for abnormalities of the prostate stitute a complete medical examination or diagnosis. I have received of PSA testing and exam, and have been given the opportunity to ensed physician or a licensed medical professional. I understand that DRE and PSA test, no test is completely accurate in the detection of roblem, I acknowledge that I must see a physician for a complete ts of this screening test will be released only to me, and the health in, and that the confidentiality of all my medical records will be all never be released to a third party without my written consent and to those directly involved with your screening and protected from rm, fully understand its contents and agree to participate voluntarily.
PSA Alone	PSA & DRE

Patient Signature Witness Signature Date Signed/Witnessed

Please Fill In Patient Data:		
NAME:		
<b>DATE OF BIRTH:</b> /		
AGE		
SOCIAL SECURITY #: XXX - XX -		

# **TEST NAME: PSA**

Frequency	Ordering MD	Collected by:	Collect:
(X ) Routine ( ) Stat ( ) Urgent	David Golombos, MD		Date & Time

**Prostate Cancer Screening Questionnaire**(All information provided below will be kept confidential and protected in accordance with applicable Federal Law)

SECTION 1 (To be completed by participant)				
First Name Middle Initial Last Name				
<b>Date of Birth</b> /	/ Age:			
Mailing Address:		Apt#		
City State	Zip Code			
Phone # _()		digits of Social Secu	urity #	
Race (Check one)  Marital Status (Check one)  Research (Please circle Y or N)				
White/Caucasian Black/African-American Hispanic/Latino Asian/Oriental Other/ Not specified	Married Single Divorced Widowed	G (Check one)	May we contact you regarding participation in prostate cancer research studies?	
<b>Medical History</b> – (Please enter or circle $Y$ or $N$ where appropriate)				
Prostate History  Please circle Y or N  Did you have a PSA test and/or rectal exam in the last 3 years? Y N  1. Ever have a Prostate Infection (Prostatitis)? Y N  2. Enlarged Prostate (BPH)? Y N  3. Prostate Surgery for BPH? Y N  4. *Prostate Biopsy		Family History of Cancer Circle Y(Yes), N(No) or ?(Unknown) for each below:  1. Father's father had prostate cancer? Y - N - ?  2. Father's brother(s) had prostate cancer? Y - N - ?  3. Father had prostate cancer? Y - N - ?  4. Brother had prostate cancer? Y - N - ?  5. Mother's family had prostate cancer? Y - N - ?  6. Mother's family had breast cancer? Y - N - ?  7. Mother had breast cancer? Y - N - ?		
Year Result? Negative Positive  If your results were Positive for Prostate Cancer, please indicate treatment(s) below:		Medications (Check all that apply)  SELECT study participants: please skip this item  1. Cardura® (doxazosin)		
Treatment Y or N If Yes, Dates  5. Brachytherapy 6. Radiation 7. Hormones 8. Radical Prostatectomy 9. Watchful Waiting		2. Hytrin® (terazosin)  3. Flomax® (tamsulosin)  4. Uroxatral® (alfuzosin)  5. Proscar®/Propecia (finasteride)  6. Avedatt® (dutastoride)		
Have you ever had any genetic tests for Prostate Cancer? Y N  7. Jalyn (dutasteride/tamsulosin)				
PCA3, urine test: Y N		8. Rapaflo (silodosin)		
4KScore, Blood Test: Y N			,	
Others:		.10110 01 1110 400		

### **Urinary Symptom Assessment**

Over the past month, how often have you...... (Circle one for each question)

Over the past month, now often have you (Circle one for each question)					
Never	Less than 1 time in 5	Less than half the time	Half the time	More than half the time	Almost always
Had the sensation of not emptying your bladder					•
completely after you finish urinating?0	1	2	3	4	5
Needed to urinate again in less than 2 hours? 0	1	2	3	4	5
Found that you stopped and started again several					
times when you urinate? 0	1	2	3	4	5
		_		_	_
Found it difficult to postpone urination? 0	1	2	3	4	5
Had a weak urinary stream?0	1	2	3	4	5
Had to push or strain to begin urinating? 0	1	2	3	4	5
How many times do you typically get up to urinate from					
the time you go to sleep until you rise in the morning?	0 1	2		3	4 5
Total Urinary Symptom Score:				_	
At present, are you comfortable with your current urinary situation?Yes No				_	

First Name	_ Middle Initial	_ Last Name	Date of Birth//		
If you would like and consent to having the results of your PSA blood test and Digital rectal exam sent to your physician, Please complete: (Must Print Clearly)					
Physician Name:					
Physician Address:					
Tel					
		ible physician address will not be maile			
		(To be completed by Physician)			
Digital Rectal Exam Results:					
Normalo	BPH	20–30 g.o 30 (2+)			
Declined/Refused	0	(2+)	(3+) (4+)		
		OR			
Digital Rectal Exam Results:	(Post Prostate C	ancer Treatment)			
Normal, expected results after	Tx (no further atte	ntion required)o			
Abnormal, not acceptable resu	Its after Tx (further	attention required)	0		
		OR			
*Abnormality	(Cor	nplete for abnormal DRE only)			
Asymmetry	R>L o	L > R o	Base		
IndurationGenerali	zed o Localized	o (indicate location(s)▶	vesicle		
Nodule(s)Solit	ary o Multiple	o (indicate location(s)▶	5 6		
HardnessF	irm o Moderate	o Hard o	3 4		
			L 1 2 R		
Physician's Signature	Da	te//			
Additional Physician's notes, if necessary:					
			_		
	Section 3	: Follow Up (If applicable)			
Indication: Abnormal DRE	PSA □ PSAV	□ IPSS □			
R.N. Signature:		Date/			